NCT02326233View on ClinicalTrials.gov

Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

190

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Healthy
Interventions
BIOLOGICAL

Pen of SB5

BIOLOGICAL

PFS of SB5

Trial Locations (2)

Unknown

Samsung Investigational Site, Antwerp

Samsung Investigational Site, Auckland

All Listed Sponsors
lead

Samsung Bioepis Co., Ltd.

INDUSTRY

NCT02326233 - Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects | Biotech Hunter | Biotech Hunter